Geron Corporation (NASDAQ: GERN) today announced the presentation of interim data from its ongoing trial of imetelstat (GRN163L), a telomerase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE